Free Trial
NYSE:DVA

DaVita (DVA) Stock Price, News & Analysis

DaVita logo
$175.53 +5.25 (+3.08%)
Closing price 03:59 PM Eastern
Extended Trading
$174.58 -0.96 (-0.54%)
As of 07:53 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About DaVita Stock (NYSE:DVA)

Key Stats

Today's Range
$170.00
$176.48
50-Day Range
$146.76
$175.53
52-Week Range
$105.82
$176.48
Volume
639,442 shs
Average Volume
537,367 shs
Market Capitalization
$14.39 billion
P/E Ratio
18.94
Dividend Yield
N/A
Price Target
$161.80
Consensus Rating
Hold

Company Overview

DaVita Inc. provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpatient, hospital inpatient, and home-based hemodialysis services; operates clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers. In addition, the company offers integrated care and disease management services to patients in risk-based and other integrated care arrangements; clinical research programs; physician services; and comprehensive kidney care services. Further, it engages in the provision of acute inpatient dialysis services and related laboratory services; and transplant software business. The company was formerly known as DaVita HealthCare Partners Inc. and changed its name to DaVita Inc. in September 2016. DaVita Inc. was incorporated in 1994 and is headquartered in Denver, Colorado.

DaVita Stock Analysis - MarketRank™

See Top Rated MarketRank™ Stocks
78th Percentile Overall Score

DVA MarketRank™: 

DaVita scored higher than 78% of companies evaluated by MarketBeat, and ranked 240th out of 934 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    DaVita has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on 1 buy rating, 3 hold ratings, and 1 sell rating.

  • Amount of Analyst Coverage

    DaVita has only been the subject of 1 research reports in the past 90 days.

  • Read more about DaVita's stock forecast and price target.
  • Earnings Growth

    Earnings for DaVita are expected to grow by 15.76% in the coming year, from $9.71 to $11.24 per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of DaVita is 18.94, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 110.73.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of DaVita is 18.94, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 89.03.

  • Price to Earnings Growth Ratio

    DaVita has a PEG Ratio of 0.82. PEG Ratios below 1 indicate that a company could be undervalued.

  • Price to Book Value per Share Ratio

    DaVita has a P/B Ratio of 12.88. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

  • Read more about DaVita's valuation and earnings.
  • Percentage of Shares Shorted

    5.63% of the float of DaVita has been sold short.
  • Short Interest Ratio / Days to Cover

    DaVita has a short interest ratio ("days to cover") of 5.8.
  • Change versus previous month

    Short interest in DaVita has recently increased by 9.16%, indicating that investor sentiment is decreasing significantly.
  • Dividend Yield

    DaVita does not currently pay a dividend.

  • Dividend Growth

    DaVita does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    5.63% of the float of DaVita has been sold short.
  • Short Interest Ratio / Days to Cover

    DaVita has a short interest ratio ("days to cover") of 5.8.
  • Change versus previous month

    Short interest in DaVita has recently increased by 9.16%, indicating that investor sentiment is decreasing significantly.
  • News Sentiment

    DaVita has a news sentiment score of 0.70. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.59 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 8 news articles for DaVita this week, compared to 9 articles on an average week.
  • Search Interest

    Only 7 people have searched for DVA on MarketBeat in the last 30 days. This is a decrease of -30% compared to the previous 30 days.
  • MarketBeat Follows

    Only 13 people have added DaVita to their MarketBeat watchlist in the last 30 days. This is a decrease of -19% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, DaVita insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    Only 2.00% of the stock of DaVita is held by insiders.

  • Percentage Held by Institutions

    90.12% of the stock of DaVita is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about DaVita's insider trading history.
Receive DVA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for DaVita and its competitors with MarketBeat's FREE daily newsletter.

DVA Stock News Headlines

Vladimir Lenin was right…
The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold $3 billion of Amazon… it’s why Nvidia’s CEO just sold $713 million... and it’s why Zuckerberg just sold $1.3 billion in Meta stock. The financial establishment doesn’t want you to know about this… but a controversial new documentary just pulled back the curtain and exposed what’s really going on. It’s called The Final Frontier.
Brokerages Set DaVita Inc. (NYSE:DVA) Target Price at $161.80
DaVita Earnings Preview: What to Expect
See More Headlines

DVA Stock Analysis - Frequently Asked Questions

DaVita's stock was trading at $149.55 at the beginning of the year. Since then, DVA stock has increased by 17.4% and is now trading at $175.53.
View the best growth stocks for 2025 here
.

DaVita Inc. (NYSE:DVA) released its earnings results on Tuesday, October, 29th. The company reported $2.59 EPS for the quarter, missing analysts' consensus estimates of $2.76 by $0.17. The company's revenue for the quarter was up 4.6% on a year-over-year basis.
Read the conference call transcript
.

The following companies are subsidiaries of DaVita: Northwest Physicians Network, Purity Dialysis, Family Health Care of Central Florida, Healthcare Partners, Gambro Healthcare, Aberdeen Dialysis LLC, Accountable Kidney Care LLC, and more.

DaVita's top institutional shareholders include KBC Group NV (0.39%), Nordea Investment Management AB (0.32%), Wedge Capital Management L L P NC (0.27%) and abrdn plc (0.22%). Insiders that own company stock include Javier Rodriguez, Michael David Staffieri, Joel Ackerman, Kathleen Alyce Waters, James O Hearty, Charles Berg, John M Nehra, Phyllis R Yale, Barbara J Desoer and Paula A Price.
View institutional ownership trends
.

Shares of DVA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that DaVita investors own include Humana (HUM), American Water Works (AWK), Voyager Therapeutics (VYGR), Waste Connections (WCN), The RMR Group (RMR), TotalEnergies (TTE) and DiamondRock Hospitality (DRH).

Company Calendar

Last Earnings
10/29/2024
Today
1/27/2025
Next Earnings (Estimated)
2/11/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Sector
Medical
Industry
Miscellaneous health & allied services, not elsewhere classified
Sub-Industry
Health Care Services
CUSIP
23918K10
Employees
70,000
Year Founded
1999

Price Target and Rating

Average Stock Price Target
$161.80
High Stock Price Target
$175.00
Low Stock Price Target
$145.00
Potential Upside/Downside
-7.9%
Consensus Rating
Hold
Rating Score (0-4)
2.00
Research Coverage
5 Analysts

Profitability

Net Income
$691.53 million
Pretax Margin
11.10%

Debt

Sales & Book Value

Annual Sales
$12.14 billion
Cash Flow
$17.53 per share
Book Value
$13.63 per share

Miscellaneous

Free Float
80,360,000
Market Cap
$14.40 billion
Optionable
Optionable
Beta
0.92

Social Links

7 Stocks to Buy And Hold Forever Cover

Enter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report

This page (NYSE:DVA) was last updated on 1/27/2025 by MarketBeat.com Staff
From Our Partners